CurrentAvMedPolicy Pub. 100-2

Canakinumab (Ilaris) prior authorization for sJIA and AOSD

Customize your policy alerts

Sign up for AvMed Policy Pub. 100-2 alerts

Get alerted when Policy Pub. 100-2 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This form and policy govern prior authorization and step-edit requirements for providing canakinumab (Ilaris) for members with systemic juvenile idiopathic arthritis (sJIA) or adult onset Still's disease (AOSD) through AvMed. It affects prescribers seeking medical benefit coverage for Ilaris and specifies clinical criteria, documentation, and review periods.

Policy Summary

PayerAvMed

PolicyCanakinumab (Ilaris) prior authorization for sJIA and AOSD

Policy CodePolicy Pub. 100-2

Change TypeNo material changes

Effective Date

Next Review Date

Key ActionPrescriber must submit labs (CRP, ESR), diagnostics, and progress notes; prior authorization required for J0638.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

3 moInitial approval duration

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentAvMedPolicy Pub. 100-2

Canakinumab (Ilaris) prior authorization for sJIA and AOSD

Customize your policy alerts

Sign up for AvMed Policy Pub. 100-2 alerts

Get alerted when Policy Pub. 100-2 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerAvMed

PolicyCanakinumab (Ilaris) prior authorization for sJIA and AOSD

Policy CodePolicy Pub. 100-2

Change TypeNo material changes

Effective Date

Next Review Date

Key ActionPrescriber must submit labs (CRP, ESR), diagnostics, and progress notes; prior authorization required for J0638.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

3 moInitial approval duration

Coverage Criteria for Canakinumab (Ilaris)

Initial therapy — Systemic Juvenile Idiopathic Arthritis (sJIA)

Covered when ALL of the following are met for pediatric members:

Age: Member aged 2 to 17 years

Duration of disease: Persistent sJIA activity for a minimum of six (6) months; date of diagnosis must be noted

Prior therapies: Trial and failure of NSAIDs and corticosteroids for >3 months consecutively within the last 4 months (paid claims will be reviewed for verification)

Joint activity: Either ≥5 active joints with concomitant fever for at least 2 weeks within the last 3 months OR >2 active joints with concomitant fever for at least 5 days plus trial of prednisone or equivalent 0.5 mg/kg/day or 30 mg/day within the last 3 months

Inflammatory markers: CRP >15 mg/L and ESR >45 mm/hr within the last 2 months

Fever >38°C (100.4°F) for at least 2 weeks within the last 2 months

Prior biologic failure: Documented failure of Kineret (anakinra) and either Arcalyst (rilonacept) or Actemra (tocilizumab); failure defined as paid claims for at least 6 months and lack of response in labs

Exception: History of anaphylactic reaction to Kineret, Arcalyst, or Actemra or development of severe skin reactions (Stevens-Johnson syndrome)

Initial therapy — Adult Onset Still's Disease (AOSD)

Covered when ALL of the following are met for adult members:

Age: Member aged 18 to 75 years

Diagnostic features: Member must meet at least two: fever >39°C lasting ≥1 week; arthralgia/arthritis ≥2 weeks; typical rash; leukocytosis >10,000/mm3 with >80% PMNs

Disease activity: DAS28 ≥3.2 at screening

Inflammatory markers: CRP >15 mg/L and ESR >45 mm/hr within the last 2 months

Joint counts: At least 4 painful and 4 swollen joints for at least 2 weeks within the last 3 months

Reauthorization / Continuation criteria

Covered for continued therapy when ALL of the following are met:

For sJIA: Documentation showing decreased ESR to <30 mg/L and ESR <13 mm/h and decreased number of swollen joints

For AOSD: Documentation showing decreased ESR to <30 mg/L and ESR <13 mm/h, decreased number of swollen joints, and DAS28 decreased to <2.6

Documentation submission: Refax form with documentation of CRP or ESR along with progress notes to document therapy effectiveness for continued 12-month approval; progress notes and labs documenting anaphylaxis or SJS must be submitted

Use of free or manufacturer samples to start therapy does not satisfy the plan's step-edit or prior authorization requirements. Samples will not be accepted as evidence of a trial or failure of prior therapies when verifying treatment history.

All required clinical documentation — including lab results, diagnostics, and chart or progress notes — must be submitted with the request. Authorization may be delayed or denied if the information provided is incomplete, incorrect, or illegible.

Coding and Dose Information

Requested drug HCPCSHCPCS

J0638

Canakinumab

inv-07: CRP

CRP threshold>15 mg/L within the last 2 months

ContextRequired for both sJIA (pediatric) and AOSD (adult) initial-therapy criteria

DocumentationCRP result must be included with submission to support approval or reauthorization

inv-08: ESR

ESR threshold>45 mm/hr within the last 2 months

ContextRequired for both sJIA (pediatric) and AOSD (adult) initial-therapy criteria

Documentation

What Providers Must Do

Prior Authorization

Prior authorization and site‑of‑care for Ilaris (J0638)

Canakinumab (Ilaris) (HCPCS J0638) requires prior authorization; it is designated non‑preferred under the medical benefit and “medication can ONLY be provided by a Physician's office.”

HCPCS code: J0638
Non‑Preferred (Medical)
Site‑of‑care: must be provided by physician's office

Step Therapy

Verification of prior therapies — claims or chart notes

Prior therapies will be verified through pharmacy paid claims or submitted chart notes; note that use of free samples to initiate therapy does not meet step‑edit/preauthorization criteria.

Verification via pharmacy paid claims or submitted chart notes
Samples used to initiate therapy do NOT meet preauthorization/step‑edit criteria

Background

Systemic juvenile idiopathic arthritis (sJIA) and adult onset Still's disease (AOSD) are inflammatory disorders that commonly present with fevers, arthritis or arthralgia, and elevated inflammatory markers (CRP, ESR). Canakinumab (an IL‑1β inhibitor) is requested for treatment of sJIA in pediatric members and AOSD in adults when specific diagnostic features, disease activity thresholds, and prior‑therapy requirements are met.

Requests for canakinumab must document the clinical features and objective inflammation measures described in the criteria, and authorization decisions will rely on submitted labs, diagnostics, and chart notes to demonstrate disease activity and prior treatment history.

Definitions

inv-15: Anaphylaxis

DefinitionAnaphylaxis is defined as an emergency department (ER/ED) visit due to throat or tongue swelling and/or shortness of breath

Use in criteriaHistory of anaphylactic reaction to Kineret, Arcalyst, or Actemra is an exception in initial-therapy criteria

Documentation requirementProgress notes or documentation of the ED visit must be submitted to support the history of anaphylaxis